BioLife CHRO has 931 shares withheld for taxes

BioLife Solutions Inc. Chief Human Resources Officer Sarah Aebersold reported a routine tax-related share disposition.

Accepted by SEC EDGAR 03/23/2026 - 05:08 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

BioLife Solutions Inc. Chief Human Resources Officer Sarah Aebersold reported a routine tax-related share disposition. On the release of restricted stock units, the company withheld 931 shares of common stock to cover her tax obligations at $19.12 per share. After this withholding, she directly owns 92,429 shares. This was not an open-market sale but a standard mechanism tied to equity compensation vesting.

Insider Trade Summary

Exercise Price or Tax Liability: 931 shares

Exercise Price or Tax Liability 1 txn

Insider Aebersold Sarah

Role Chief Human Resources Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	931	$19.12	$18K

Holdings After Transaction: Common Stock — 92,429 shares (Direct)

Holdings Before and After: Common Stock, 93,360 to 92,429 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioLife Solutions (BLFS) report for Sarah Aebersold?

BioLife Solutions reported that Chief Human Resources Officer Sarah Aebersold had 931 shares withheld to cover taxes upon the release of restricted stock units. This is a routine equity compensation event and not an open-market stock sale.

How many BioLife Solutions (BLFS) shares were involved in Sarah Aebersold’s Form 4?

The Form 4 shows 931 shares of BioLife Solutions common stock were withheld. These shares were retained by the company to satisfy tax withholding obligations triggered when Aebersold’s restricted stock units released and became taxable.

At what price were Sarah Aebersold’s withheld BLFS shares valued?

The 931 BioLife Solutions shares withheld for taxes were valued at $19.12 per share. This value is used solely for calculating the tax obligation associated with the release of restricted stock units, not as an open-market transaction price.

How many BioLife Solutions (BLFS) shares does Sarah Aebersold own after this transaction?

Following the tax-withholding disposition, Sarah Aebersold directly owns 92,429 shares of BioLife Solutions common stock. This figure reflects her remaining equity stake after 931 shares were withheld to satisfy tax liabilities from restricted stock unit vesting.

Was Sarah Aebersold’s BLFS Form 4 transaction an open-market sale?

No, the transaction was not an open-market sale. The 931 shares were withheld by BioLife Solutions to pay Sarah Aebersold’s tax obligations when restricted stock units were released, a common administrative step in equity compensation plans.

What does the tax-withholding transaction mean for BioLife Solutions (BLFS) investors?

The tax-withholding transaction is largely administrative and compensation-related. It reflects shares withheld to cover Sarah Aebersold’s tax bill from restricted stock unit vesting and does not indicate discretionary buying or selling activity in BioLife Solutions shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aebersold Sarah

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WASHINGTON 98021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/19/2026		F		931	D	$19.12(1)	92,429	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Remarks:

	/s/ Sarah Aebersold	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)